Aarti Drugs Limited (524348) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Ladies and gentlemen, good day, and welcome to Q2 and H1 FY '27 Earnings Conference Call of Aarti Drugs Limited. [Operator Instructions] Please note that this conference is being recorded. Before we begin, a brief disclaimer. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and it may involve risks and uncertainties that are difficult to predict. I now hand the conference over to Mr. Adhish Patil, Managing Director of Aarti Drugs Limited. Thank you and over to you, sir.
Thank you. Good morning, everyone and thank you for joining us for Aarti Drugs Limited earnings conference call for the second quarter and first half of FY '27. With me today are Mr. Harshit Savla, our Joint Managing Director; Mr. Harit Shah, Whole-Time Director; Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; and our investor relations adviser, SGA. Our results and investor presentation for the quarter ended 30th September, 2026 have been filed with the stock exchanges and are also available on our website. I hope you have had a chance to go through them. I am pleased to report that Q2 FY '27 has been a milestone quarter for Aarti Drugs Limited. For the first time ever, our total consolidated revenue was at INR 829 crores in a single quarter, 27% higher than a year ago. Operating environment remained supportive throughout the quarter. Developments in West Asia kept API prices firm across the industry, while customers increasingly prioritized reliable and uninterrupted supply of APIs. Aarti Drugs was well placed to benefit from this, delivering a 16% improvement in realizations year-on-year, alongside a volume growth of 5%. Just as important as the recovery in our margins, EBITDA grew 63% to INR 138 crores, the highest quarterly EBITDA we have ever reported with our EBITDA margin for the quarter reaching 16.6%, up 370 basis points year-on-year basis and the highest we have achieved in nearly 6 years. Profit after tax rose 83% to INR 82.8 crores. Our focus remains firmly on what is within our control, that is growing volumes, improving our product mix and market mix and lowering our costs through backward integration, process improvement and energy optimization. Our API business, which remains our largest segment, grew 17% to INR 605 crores compared with INR 516 crores in Q2 FY '26. Our Specialty Chemicals business continued to scale up with the support of our Sayakha facility and grew 92% to INR 72 crores from INR 37 crores a year ago. Our formulations business also had an excellent quarter, growing 58% from INR 82 crores in Q2 FY '26 to INR 130 crores in Q2 FY '27, led by exports, which rose 73% year-on-year. Now let's talk about some projects. Let me begin with our methylamines facility at Sayakha. During the quarter, the plant operated at around 72% utilization and captive consumption of our antidiabetic portfolio rose to around 85%. These gains in product mix, backward integration and cost efficiency are structural and they will stay with us even as the pricing environment normalizes over time. I would like to highlight how quickly this facility has come together. We commissioned it in September last year and within roughly a year, a large share of our key intermediates for metformin, which we earlier bought from outside, is now being made in-house. This gives us better control over the cost, quality and availability of inputs for one of our most important products and it strengthens our position as a dependable, integrated supplier for our customers. We are now working to improve utilization of the other products at the site as well. At the Tarapur facility, the improvements we spoke earlier are now underway and we have started producing technical-grade methyl salicylate as well. We have manufactured roughly around 85 tonnes so far in the last quarter. We are also expanding our USFDA approved block at Tarapur by building an adjacent block, which will more than double its capacity. This expansion includes 3 new multipurpose plants, which will give us the flexibility to make a wider range of products for regulated markets. We expect the project to take around 18 to 20 months with commercial production targeted towards the end of FY '29. At Sarigam, we are increasing our metformin capacity from 1,400 tonnes per month to 1,700 tonnes per month, with commercialization planned in early FY '28. Alongside this, we are adding a dedicated 500 tonnes per month USFDA compliant block by the end of FY '28. And our USFDA DMF for metformin is under preparation. At our facility in Baddi in Himachal Pradesh, we are executing a brownfield expansion, which involves utilizing an adjacent plot to nearly double the current oral solid dosage manufacturing capacity and support a long-term formulations revenue target. With a stronger, more integrated platform and capacity additions lined up at Tarapur, Sarigam and Baddi, we enter the second half of the year with confidence. Once this block is approved, it is expected to open the door to many of the U.S. and EU market customers. I would also like to share an update regarding our sustainability initiatives. CRISIL has assigned Aarti Drugs an ESG rating of 61 for FY '25, '26, which places us in the strong category. We see this as a recognition of the steady work our teams have put into environment, safety and governance across our sites and we will continue to build on it. With that, let me take you through our financial performance. First, we'll talk about consolidated financial highlights for Q2 FY '27. Revenue stood at INR 829 crores as compared to INR 653 crores in Q2 FY '26, reflecting a growth of 27% Y-o-Y. EBITDA stood at INR 138 crores versus INR 84 crores in Q2 FY '26, recording a growth of 63% YoY. EBITDA margin stood at 16.6%, an expansion of 370 basis points Y-o-Y basis. PAT stood at INR 83 crores as compared to INR 45 crores in Q2 FY '26, a growth of 83% Y-o-Y. PAT margin stood at 10%, an expansion of 310 basis points Y-o-Y. Now, let's speak about standalone business for Q2 FY '27. Revenue stood at INR 709 crores versus INR 579 crores in Q2 FY '26, a growth of 22% year-on-year. Standalone business contributed 84.3% to the consolidated revenue. 68% of the standalone revenue came from the domestic market and 32% from the export market. Domestic revenue grew 43% Y-o-Y while export revenue declined 5% Y-o-Y. Within the API segment, the antibiotic therapeutic category contributed 34.1%; antidiabetic, 18.2%; antiprotozoal, 18.1%; antiinflammatory, 14.8%; antifungal, 9.3% and the rest contributed 5.6% to total API sales. Consolidated financial highlights, H1 FY '27. Moving to the first half of the year, revenue stood at INR 1,532 crores as compared to INR 1,244 crores in H1 FY '26, reflecting a growth of 23% Y-o-Y. EBITDA stood at INR 235 crores versus INR 158.8 crore in H1 FY '26, recording a growth of 48% Y-o-Y. EBITDA margin stood at 15.3%, an expansion of 250 basis points Y-o-Y. PAT stood at INR 133 crores as compared to INR 99 crores in H1 FY '26, a growth of 34% Y-o-Y. PAT margin at 8.7%, an expansion of 70 basis points Y-o-Y. Now, let's talk about our formulations segment. Finally, our formulation business, which we run through our subsidiary Pinnacle Life Science, recorded a revenue of INR 130 crores in Q2 FY '27 compared to INR 83 crores in Q2 FY '26, up by 58% Y-o-Y. Exports contributed 74% to this formulation revenue. For H1 FY '27, formulation revenue stood at INR 212 crores compared to INR 163 crores in H1 FY '26, up by 30% with exports accounting for 63% of total formulation sales. With that, I would now like to open the floor for questions. Thank you.
[Operator Instructions] The first question is from the line of Candice Pereira from Dolat Capital.
So my first question is on the API business. So we had a 17% growth this quarter. So how much of it was from price and how much was it from volume growth?
Sorry, Candice, can you please repeat the question? I missed it.
Yes. So on the API business, how much is the growth from price and how much is from volume?
Okay. Yes. So for the API business on Y-o-Y basis, we saw a price growth of almost around 17% to 18% and there was a volume growth, on the overall stand-alone basis I'm talking about, and the overall volume growth was around 5% for both API and Spec Chem put together.
Okay. And for H1, it was in the same range for the first half?
So for the first quarter, what I remember, it was somewhere -- the volume growth was somewhere around 3% and rate growth was somewhere around 16% to 17% for the first quarter, Y-o-Y basis.
Okay. And the rate variance?
Yes. So the rate variance for H1 would be roughly in the range of 17%, 18%.
Okay. 17% to 18%. Also in the formulations business, the growth was quite strong this quarter. So is there any one-off?
Vishwa, would you like to answer this one?
Yes, sure. So basically, the growth has been fueled by increase in our export business, which is something that we have been working on since the last few years in opening up newer markets and we have the products under registration in various regulated and emerging markets. So which is why now we have started commercializing products in newer territories and that is what has led to the growth in the revenue as well as in the EBITDA margin. So while this was an exceptional quarter, but we believe that now with our entry into newer markets and newer products, we will be able to sustain a similar level of revenue.
Okay. So this level of revenue is sustainable for the rest of the year, right?
Right.
Okay. And our margins currently, so since this level of growth in formulations is sustainable, will our margins also be sustainable at 15% that it is now in the first half of the year?
Are you asking about the consol margins?
Overall company margins.
Yes. So the overall company margins, we do feel that 15% should be sustainable. Though for this particular quarter, we have achieved EBITDA margins of around 16.6%.
Yes. Okay. And even the gross margins?
So gross margins, what has happened is that -- gross margins, when the rates of APIs and Spec Chem goes up, there is a cost plus formula in this business. So typically, what happens when the rates go a lot higher, though the gross contribution increases, but the gross contribution margin decreases because of the base effect. But at the same time, the manufacturing overheads in percentage terms will go down. So on an overall basis, the EBITDA margins should sustain.
[Operator Instructions] The next question is from the line of [ Ankur Kumar ] from Alpha Capital.
Sir, in terms of breakup between volume and pricing, you said 17% to 18% is pricing growth. Am I clear, sir?
Yes.
And so what is our view in terms of in this current quarter and the next quarter, this kind of volume growth -- this kind of pricing growth is sustaining? Or how are we thinking?
So as of now, the pricing continues to remain stable because there were multiple factors. At the start of the war back in March month, the pricing growth was more related to gas-based products, natural gas-based products. And now the pricing growth will also be driven by the crude, whatever products are linked directly or indirectly to the crude prices. So what we feel the sales as of now is the pricing continues to remain the same.
Got it, sir. And sir, in terms of this, you are saying 15% are sustainable margin, but this quarter is 16%. So is there any inventory-related benefit in this quarter? Or why are we expecting some moderation?
Yes. Look, we are just being conservative here. Now, the thing is, for the stand-alone company, if you look back last 2 quarters, we consistently hit above 14% in each quarter on a stand-alone basis. But on the formulation side, this particular quarter, we made exceptional EBITDA margins of roughly around 28% due to good export orders. Frankly speaking, we do have a visibility of almost -- we have a pending -- export pending orders for almost 4 months more. For more than 1 quarter, we do have export orders. But we are just being conservative that even if, in a longer-term steady-state basis, even if the formulation margins come down to, let's say, 20%, even then, assuming that the formulation would now going forward be around 15%, 16% of the consol revenue and stand-alone business would be roughly around 84%, 85% of the consol revenue at 14%, even then we will be able to achieve slightly upwards of 15% margin. But having said that, we do have scope of improving the EBITDA margins at the stand-alone level as well.
Got it, sir. And those formulation 28% margin, they will sustain for 4 months and then we need more orders for that?
Yes. So if the order keeps coming, then we should be able to sustain at least in like early 20s.
Right. And we believe that apart from the 4-month order book, now that we have entry into multiple markets with multiple products, we foresee that this kind of momentum in exports will continue on the formulation side.
Got it, sir. And sir, on the API side, what kind of volume growth are we expecting going into the second half?
Frankly speaking, when we started with the year, we were targeting roughly around 10% odd volume growth at the company level. Though first half, we just were able to achieve 3% and 5%, respectively, volume growth in the stand-alone segment. And that is mainly because the prices of all the specialty chemicals and APIs have gone up. Typically the purchasing people at the formulation side, they try to refrain overstocking the product because the prices have suddenly gone up due to geopolitical reasons. So there is a waiting game here. So once they start believing that this is a new normal, then the volume growth and the demand should start to come in. And in that case, we can expect, let's say, in high single-digit volume growth. But as of now, even we are not that sure. So let's say, we will assume somewhere between 5% to 10% volume growth.
[Operator Instructions] The next question is from the line of [ Akash ] an individual investor.
I want to know about what is the company's aspiration or the vision to move towards complex APIs and rather than the volume-driven APIs, let's say 2030 onwards. Is the management planning to move towards any complexity problem which are very complex APIs in the manufacturing? So I want to know about your vision for the complexity of APIs.
Yes. Thank you for that. That is a very interesting question, actually. So as you know that traditionally Aarti Drugs was always strong in bulk volume APIs because of our engineering and process improvement strength. So going forward, we are actually working on our business plan for the next, you can say, 5 to 7 years, which includes introducing newer molecules -- a mixed bucket of molecules. Some of them would be similar to what we do where our strength lies. Some of them would be a bit more niche molecules, natives. And we are also trying to develop competencies on a CDMO platform. So for that, strengthening our R&D further and ability to carry out more complex [ situation ]. So we are thinking in those lines. So probably within 4, 5 months, we will have a clearer picture of what will be the CapEx or capital assignment towards this kind of projects. But definitely, if you ask from 3 to 5 years horizon, so we will be working in that direction. And apart from that, one more thing what we are parallelly doing is that we are trying to increase our regulatory presence, means basically trying to increase the presence in regulated markets for our existing molecules. So in most of our existing molecules, though we might be cost leaders, but we are mainly catering ROW market and to some extent, regulatory market. But we would like to increase that footprint in the regulated market so that it can increase our margins further and it will make it stable as well.
[Operator Instructions] The next question is from the line of Resham Jain from VVD Asset Managers.
Also congratulations on your elevation as the Managing Director of the company. So I have a few questions. The first one is on the formulation business. We did mention in the previous calls about the oncology and the USFDA approval. And you mentioned that the USFDA-related dossier filing is also going on at the formulation facility. Has that also contributed in this quarter or that is still to come?
That is still to come. Yes. Vishwa can clarify.
Yes, I'll mention. So we have a small contribution in this quarter from the U.S. oncology product, but it is a very small amount as of now because it has just very recently been launched. So we expect that in the coming 3 to 6 months, the U.S. revenue would increase with the one product that we have in the market. And then we have another ANDA, which is due for approval in the next few months. And then we have a filing plan of another 4 to 5 oncology products in the rolling 12 months. So the U.S. business has initiated, but it is yet to be ramped up to a significant level.
Understood. And in your annual report, you mentioned about your aspiration to take the formulation business to INR 1,000 crores. With the traction you have seen in Q2 and in Q3 probably, as you mentioned, with the order book, you think that INR 1,000 crore aspiration can happen much faster than that? Because this kind of traction we have not seen in the last few years.
Right. So yes, that is the belief that we think that we can achieve the INR 1,000 crore landmark earlier than what we have published. And we are also building up our capacities. So we were at a stage that our capacities were almost running at full scale. So like Adhish mentioned, we have a brownfield expansion going on, which by the mid of next year should double our capacities. And that clubbed with the higher utilization of our oncology facility, which is currently having only 1 or 2 products commercialized, once that ramps up, which we see happening in the very near future, we will definitely be able to achieve the INR 1,000 crore mark.
And the oncology would also have higher margin profile.
Yes, right. At the gross level, oncology should have slightly higher margins than our current business.
Okay. Got it. The second question is with respect to the salicylic acid. Has there been any update in terms of antidumping duty? Because that was something which was, in a way, a challenge for us.
Harshit bhai, would you like to answer this question?
Yes. We will be submitting with the September report. So we have to -- additionally 9 months data, we have to submit. So after now the result is published, we will be submitting the antidumping duty now. For antidumping duty, they need more, 9 months data.
Okay. So when will [ DGTR or any ]...
In our initial meeting, they put it by -- they will initiate before the year-end, December.
Okay. Okay. So maybe it will take another 6 months or so, because after that 90 days will be taken by the Ministry of Finance.
Yes, yes. First, they will initiate, and then they will take another 3- to 6-month period to get into it.
Okay. Got it. The last question is for Adhish. The cash generation which we are now having and most of the CapExes which we have undertaken in the last 3, 4 years are almost over. What are the plans going forward? Because you did mention about the 5, 7 years vision which you are planning to lay out. But the yearly cash generation is significant now. So from that context, what is the CapEx plan for '27 and '28?
Yes. So for the first half, we barely managed to do around -- roughly near about INR 90 crores of operating cash flow for both the companies, that is stand-alone as well as formulation. And it was more or less equal in both the stand-alone business and the formulation business. And going forward, for the stand-alone business, as we said that we will be going in for the expansion of USFDA block with 3 more lines. It can have a revenue potential anywhere between INR 180 crores to INR 200 crores on a full-scale basis. It will be a multipurpose facility. Plus, we are expanding our metformin capacities and we are making it USFDA compliant as well. So both these projects are aimed towards regulatory markets -- and mainly, we foresee enough business from our existing molecules as such. So we already know the chemistry. But having said that, we will be also introducing newer products, more niche products into our multipurpose USFDA block. And a few months down the line, we will be ready with few more plans for CapEx. One is creating a CDMO block for intermediates and Spec Chem. And also, we plan to invest quite heavily in R&D in the formulation division as well.
The next question is from the line of [ Jay Jain from JJ Capital ].
Sir, congratulations on a great set of results. Sir, in your speech, you mentioned about realization gain, and we know that some API and KSM prices jumped sharply when the conflict began. Sir, how rapidly are we able to pass on these price increases? Also, if you can quantify how much of your Q2 realization gain comes from contracts signed at peak prices and how much of it resets if the crude prices lowers in H2 FY '26?
Yes. So I'll give you a general sense of our order books. So typically, in exports, we generally have pending orders of roughly around 2.5 to 3 months, whereas in the domestic market, it is slightly less than 1 month, or you can say on an average 1 month. So that is the prices which are fixed going forward. But whenever there are price hikes in the input cost, in the input raw materials, in intermediates, that time, all the newer contracts get negotiated at the higher rates. So in terms of passing on the prices, it happens pretty quickly for the new orders which we take from that point onwards. Only for the pending orders, we have to supply those materials at a lower rate. But at the same time, we also hold RM inventory of roughly around 40, 50 days. So some bit of it is -- that risk is mitigated because of our inventories. But I am not able to exactly quantify it for you because since we operate in so many products, it is difficult for me to quantify...
Got it, sir. And just one more, since you spoke about raw materials. So going forward, are we looking to stock up more inventory or raw materials?
No. Ideally speaking, we should not because the prices are high. I think we should operate in a way that our raw material booking matches with our sales booking and not take call. Because if we take a call and if the market turns the other way, then there can be huge losses.
Got it. Sir, just last question. If you can help us understand how much of the EBITDA margin contribution has come from product mix change versus operational efficiency versus pricing benefit?
Okay. So if we talk about our stand-alone business, which is like 84% to the total consol revenues, so in that, the major -- some bit of gains have come from operational energy optimizations. We have undertaken a few projects. In fact, a few more projects will be upcoming, like our solar projects. So they will also start contributing in this quarter, in the December quarter, that is. And so the gross contribution level has also increased, no doubt about that. So I would say, let's say, around 50 basis points might be because of the increase in the overall gross contribution and rest is because of the lowering of manufacturing cost. And whereas formulations are concerned, it is mainly to do with the gross contribution.
[Operator Instructions] The next question is from the line of [ Rohit from SK Security and Services ].
Congratulations on good set of numbers. So I have only one question. On oncology segment, could you please provide more details like product molecules that we are targeting and the client profiles we aim to work with and maybe which geographies, timelines? And what could be the contribution to our revenue by FY '29 or '30?
So contribution to revenue from the oncology at an, let's say, FY '30 level, we estimate it to be between late 30s to early 40% maybe. And basically for us, the oncology portfolio consists of about 25 to 30 molecules that are at various stages of developments and filings. Many of them are the existing APIs that are being manufactured within our group companies. So basically, these are the [ nib families and cyclic ] families of oncology oral solids. And we are -- in some countries, we are doing our own filings and in other markets, it is a B2B-driven model where we are working with most of the leading players in those markets.
Got it, sir. And geographies?
So like we mentioned, we are basically looking at entire regulated market space from U.S., EU, U.K. and Latin America, Middle East, Asian markets. So that is a widespread global strategy.
As there are no further questions from the participants, I now hand the conference over to the management for closing comments. Over to you, sir.
Thank you, everyone, for joining us today on this earnings call. We appreciate your interest and all the questions you asked regarding the financial results of Aarti Drugs and about our future. If you have any further queries, please contact SGA, our investor relations adviser. Thank you and wish you a happy Diwali.
Thank you very much. On behalf of Aarti Drugs Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 260,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Aarti Drugs Limited earnings transcripts and 260,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $145 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.